One-Year combo pill strategy may boost CLL remission rates

NCT ID NCT06520098

Recruiting now Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 100 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). Half will keep taking the BTKi alone, while the other half will add a second pill called venetoclax for one year. After that year, both pills are stopped and participants are closely watched. The goal is to see if the combination leads to more complete remissions and less fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Show contact details

Locations

Durham VA Medical Center, Durham, NC
RECRUITING

Durham, North Carolina, 27705-3875, United States

Contact Email: •••••@•••••
Kansas City VA Medical Center, Kansas City, MO
RECRUITING

Kansas City, Missouri, 64128-2226, United States
San Francisco VA Medical Center, San Francisco, CA
RECRUITING

San Francisco, California, 94121-1563, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WA
RECRUITING

Seattle, Washington, 98108-1532, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.